2seventy bio Statistics
Total Valuation
2seventy bio has a market cap or net worth of $231.93 million. The enterprise value is $271.61 million.
| Market Cap | 231.93M |
| Enterprise Value | 271.61M |
Important Dates
The next estimated earnings date is Wednesday, May 1, 2024, after market close.
| Earnings Date | May 1, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
2seventy bio has 51.31 million shares outstanding. The number of shares has increased by 38.27% in one year.
| Shares Outstanding | 51.31M |
| Shares Change (YoY) | +38.27% |
| Shares Change (QoQ) | +0.44% |
| Owned by Insiders (%) | 2.50% |
| Owned by Institutions (%) | 98.52% |
| Float | 49.61M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.31 |
| Forward PS | 2.79 |
| PB Ratio | 0.91 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.71 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.98, with a Debt / Equity ratio of 1.01.
| Current Ratio | 3.98 |
| Quick Ratio | 3.85 |
| Debt / Equity | 1.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -65.40% and return on invested capital (ROIC) is -46.36%.
| Return on Equity (ROE) | -65.40% |
| Return on Assets (ROA) | -32.80% |
| Return on Capital (ROIC) | -46.36% |
| Revenue Per Employee | $366,376 |
| Profits Per Employee | -$794,051 |
| Employee Count | 274 |
| Asset Turnover | 0.15 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -49.04% in the last 52 weeks. The beta is 1.85, so 2seventy bio's price volatility has been higher than the market average.
| Beta (1Y) | 1.85 |
| 52-Week Price Change | -49.04% |
| 50-Day Moving Average | 5.19 |
| 200-Day Moving Average | 4.75 |
| Relative Strength Index (RSI) | 42.63 |
| Average Volume (30 Days) | 1,469,619 |
Short Selling Information
The latest short interest is 6.81 million, so 13.26% of the outstanding shares have been sold short.
| Short Interest | 6.81M |
| Short Previous Month | 5.25M |
| Short % of Shares Out | 13.26% |
| Short % of Float | 13.72% |
| Short Ratio (days to cover) | 4.53 |
Income Statement
In the last 12 months, 2seventy bio had revenue of $100.39 million and -$217.57 million in losses. Loss per share was -$4.42.
| Revenue | 100.39M |
| Gross Profit | 83.47M |
| Operating Income | -237.37M |
| Pretax Income | -217.57M |
| Net Income | -217.57M |
| EBITDA | -207.29M |
| EBIT | -217.57M |
| Loss Per Share | -$4.42 |
Balance Sheet
The company has $216.99 million in cash and $256.67 million in debt, giving a net cash position of -$39.68 million or -$0.77 per share.
| Cash & Cash Equivalents | 216.99M |
| Total Debt | 256.67M |
| Net Cash | -39.68M |
| Net Cash Per Share | -$0.77 |
| Equity / Book Value | 255.30M |
| Book Value Per Share | 4.98 |
| Working Capital | 177.99M |
Cash Flow
In the last 12 months, operating cash flow was -$166.86 million and capital expenditures -$13.87 million, giving a free cash flow of -$180.72 million.
| Operating Cash Flow | -166.86M |
| Capital Expenditures | -13.87M |
| Free Cash Flow | -180.72M |
| FCF Per Share | -$3.67 |
Margins
Gross margin is 83.15%, with operating and profit margins of -236.46% and -216.73%.
| Gross Margin | 83.15% |
| Operating Margin | -236.46% |
| Pretax Margin | -216.73% |
| Profit Margin | -216.73% |
| EBITDA Margin | -206.49% |
| EBIT Margin | -216.73% |
| FCF Margin | -180.03% |
Dividends & Yields
2seventy bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -38.27% |
| Shareholder Yield | -38.27% |
| Earnings Yield | -93.81% |
| FCF Yield | -77.92% |
Analyst Forecast
The average price target for 2seventy bio is $10.60, which is 134.51% higher than the current price. The consensus rating is "Buy".
| Price Target | $10.60 |
| Price Target Difference | 134.51% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (5Y) | 12.77% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
2seventy bio has an Altman Z-Score of -1.53 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.53 |
| Piotroski F-Score | 5 |